December 2022

Limitations of Pathologic Complete Response as Surrogate Marker
The reliability of surrogate markers has been called into question regarding their ability to consistently predict outcomes at the clinical trial level. This is especially problematic when there is a discrepancy between a clinically relevant endpoint and its ability to capture the whole effect of treatment at the patient and trial levels. Read more.


Tamoxifen Increases Risk of Endometrial, Uterine Cancers
Tamoxifen, a selective estrogen receptor modulator used as adjunctive hormonal therapy in estrogen-receptor positive breast cancer, acts like an antiestrogen on breast tissue but has estrogenic activity on the endometrium and uterus. Research has established a strong relationship between tamoxifen use and these cancers in postmenopausal women. The effect of tamoxifen on the development of endometrial and uterine malignancies, however, is controversial. Read more.

Sequential Treatment Regimen Costs for MBC
Advances in the management of metastatic breast cancer (MBC) have increased rapidly in recent years. There is little information, however, on treatment sequencing patterns of oncologic agents or on the cost that these regimens incur. A recent study identified treatment patterns by MBC subtype and associated oncologic and supportive drug costs based on cost data from the healthcare sector and Medicare. Read more.

Connect With U.S. Pharmacist
Facebook Twitter USP Google AppUSP Itunes App